Sangamo Therapeutics Inc (SGMO) Stock Analysis
Verdict: AVOID
Investment score: 18/100
Analysis as of
Is Sangamo Therapeutics Inc stock worth reviewing? The TradeMates thesis
Sangamo is a distressed biotech firm with a terminal cash burn rate, negative equity, and rapidly declining revenues. Technicals are in a free-fall, and the balance sheet suggests imminent dilution or restructuring.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Sangamo Therapeutics Inc opportunities and risks
What speaks for SGMO
- Partnership Milestone Payments
What speaks against SGMO
- Imminent Dilution or Delisting
Peers and competitors
Frequently asked questions about Sangamo Therapeutics Inc (SGMO)
Is SGMO stock a good investment?
The TradeMates model rates Sangamo Therapeutics Inc as AVOID with an investment score of 18/100. Sangamo is a distressed biotech firm with a terminal cash burn rate, negative equity, and rapidly declining revenues. Technicals are in a free-fall, and the balance sheet suggests imminent dilution or restructuring. This is algorithmic model output, not personal investment advice.
Is SGMO stock a buy?
The TradeMates model verdict for SGMO is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.